Drug
E7777
E7777 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
2
50%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Withdrawn1
Completed1
Recruiting1
Suspended1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
withdrawn125%
completed125%
recruiting125%
suspended125%
Recent Activity
1 active trials
Showing 4 of 4
suspendedphase_1
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
NCT04855253
recruitingphase_1
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT05200559
completedphase_2
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
NCT02676778
withdrawnphase_3
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
NCT01355783
Clinical Trials (4)
Showing 4 of 4 trials
NCT04855253Phase 1
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
NCT05200559Phase 1
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT02676778Phase 2
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
NCT01355783Phase 3
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4